摘要
目的:探讨膀胱癌术后吡柔比星(THP)膀胱灌注预防复发的临床疗效。方法:将90例浅表性膀胱癌术后患者随机分为A、B、C 3组,每组30例,其中A组行膀胱灌注吡柔比星治疗,30 mg/次,1次/周,共治疗8次。B组也行膀胱灌注吡柔比星治疗,且前8周治疗与A组相同,之后改为每月灌注1次,30 mg/次,连用10个月,总周期12个月。C组行膀胱灌注卡介苗(BCG)治疗,80 mg/次,1次/周,以后逐渐减少治疗次数,总周期12个月。比较3组患者的不良反应以及复发率。结果:3组患者均随访2年,其中A、B、C 3组患者1年后的复发率分别为10.0%(3/30)、6.7%(2/30)和6.7%(2/30),差异无统计学意义(χ2=1.8,P>0.05)。3组患者2年后的复发率分别为16.7%(5/30)、13.3%(4/30)和9.0%(3/30),其中A组与C组差异有统计学意义(χ2=9.2,P<0.05)。3组不良反应发生率分别为10.0%(3/30)、20.0%(6/30)和36.7%(11/30),A、B两组的不良反应少于C组(χ2=11.8,P<0.05)。结论:THP用于膀胱灌注预防膀胱癌术后复发,短期与长期疗效相比无统计学差异,且长期疗效与BCG疗效相比无统计学差异,但不良反应较少,可根据患者的具体情况用药。
OBJECTIVE：To investigate clinical efficacy of pirarubicin （THP） to prevent recurrence of bladder cancer. METHODS： Totally 90 patients treated for superficial bladder cancer patients were randomly divided into A, B, C groups with 30 cases, of which A group underwent intravesical THP treatment, 30 mg/f, once a week, were treated 8 times. B group also line THP instillation therapy, and the first 8 weeks of treatment, the same with the A group, and then once a month instead of infusion, 30 mg/f, once every 10 months, with a total course of 12 months. C group underwent intravesical instiliation of BCG （BCG） therapy, 80 mg/f, 1 times / week, then gradually reduce the number of treatments, the total course of 12 months. Compared three groups of patients and the recurrence rate of adverse reactions. RESULTS; The patients were followed for two years, including A, B, C three groups of patients 1 year after the recurrence rate was 10. 0% （3/30）, 6. 7%（2/30）, 6. 7%（2/30）. There was no significant difference （X^2=1. 8,P〉0. 05）. Three groups of patients 2 years after the recurrence rate was 16.7%（5/30） , 13.3%（4/30） , 9, 0% （3/30）, in which A groul/） and C group significantly different（X^2=9.2,P〈0.05）. Adverse reaction rates were 10. 0%（3/30）, 20.0% （6/30）, 36.7%（11/30）. A, B adverse reactions in both groups was significantly less than C group （ X^2=11.8,P〈0.05）. CONCLUSION： THP instillation for preventing recurrence of bladder cancer, short and long-term efficacy was no different, and its long-term efficacy of BCG was no significant difference in efficacy, but fewer adverse reactions, according to the specific situation of patients with drugs.
出处
《中华肿瘤防治杂志》
CAS
2011年第6期450-452,共3页
Chinese Journal of Cancer Prevention and Treatment
